Saad F, Del Rosario P, Clarke NW. Reply to Lin Ding, Bin Yang, and Xudong Yao's Letter to the Editor re: Fred Saad, Noel W. Clarke, Mototsugu Oya, et al. Olaparib plus Abiraterone Versus Placebo plus Abiraterone in Metastatic Castration-resistant Prostate Cancer (PROpel): Final Prespe Eur Urol 2023 Dec 1:S0302-2838(23)03274-8. doi: 10.1016/j.eururo.2023.
PMID: 38042647